12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Durezol regulatory update

Novartis disclosed in its 2Q12 earnings that FDA approved an sNDA for Durezol difluprednate treat endogenous anterior uveitis. The topical ophthalmic emulsion containing difluprednate is...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >